Long-Term Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome: Comparison of Liposyn III 2 Percent With Liposyn II 20 Percent
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Weight Loss, Parenteral Nutrition, Total, AIDS-Related Opportunistic Infections, Liposyn, Acquired Immunodeficiency Syndrome
Eligibility Criteria
Inclusion Criteria Concurrent Medication: Allowed: Zidovudine (AZT). All drugs used for the standard treatment of opportunistic infections. Other drugs used for the treatment of other AIDS conditions if they have been started more than 3 months prior to study entry. Patients must have: Diagnosis of AIDS. Weight loss of > 10 percent premorbid body weight. Presenting diagnosis of either opportunistic infection or Kaposi's sarcoma. Require home total parenteral nutrition (TPN) for a period of approximately 3 months. Life expectancy = or > 90 days. Prior Medication: Allowed: Zidovudine (AZT). Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: Life expectancy < 90 days. Biliary stasis. History of drug abuse. Patients with the following are excluded: Life expectancy < 90 days. Biliary stasis. History of drug abuse. Prior Medication: Excluded within 3 months of study entry: Immunomodulators. Experimental antiviral DT. History of drug abuse.
Sites / Locations
- Intracare Inc
- East Orange Veterans Administration Med Ctr